Epoetin alfa biosimilar - Claris Lifesciences

Drug Profile

Epoetin alfa biosimilar - Claris Lifesciences

Alternative Names: Epotin; Recombinant human erythropoietin - Claris Lifesciences

Latest Information Update: 01 Oct 2013

Price : $50

At a glance

  • Originator Claris Lifesciences
  • Class Antianaemics; Recombinant erythropoietins
  • Mechanism of Action Erythropoiesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Anaemia; Chemotherapy-induced anaemia

Most Recent Events

  • 05 Dec 2011 Launched prior to December 2011 for Anaemia in India (IV)
  • 05 Dec 2011 Launched prior to December 2011 for Anaemia (in premature infants) in India (IV)
  • 05 Dec 2011 Launched prior to December 2011 for Chemotherapy-induced anaemia in India (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top